- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06800313
En studie av HLD-0915 hos pasienter med metastatisk kastrasjonsresistent prostatakreft (MCRPC)
Fase 1/2 studie av HLD-0915 hos pasienter med metastatisk kastrasjonsresistent prostatakreft (MCRPC)
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Study Contact
- Telefonnummer: 844-434-4210
- E-post: Participate-In-This-Study1@its.jnj.com
Studiesteder
-
-
Colorado
-
Colorado Springs, Colorado, Forente stater, 80909
- Rekruttering
- Rocky Mountain Cancer Center
-
Denver, Colorado, Forente stater, 80218
- Rekruttering
- Sarah Cannon Research Institute 1
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06511
- Rekruttering
- Yale University
-
-
Florida
-
Sarasota, Florida, Forente stater, 34232
- Rekruttering
- Florida Cancer Specialists
-
-
Louisiana
-
Metairie, Louisiana, Forente stater, 70006
- Rekruttering
- XCancer Research Network LCMC Health EJGH
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Dana Farber Mass General Brigham Cancer Care Inc
-
-
Michigan
-
Grand Rapids, Michigan, Forente stater, 49546
- Rekruttering
- South Texas Accelerated Research Therapeutics, LLC (START)
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68130
- Rekruttering
- Urology Cancer Center, PC
-
-
New York
-
Long Island City, New York, Forente stater, 11101
- Rekruttering
- Memorial Sloan Kettering Cancer Center
-
Syracuse, New York, Forente stater, 13210
- Rekruttering
- Associated Medical Professionals
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Rekruttering
- Duke University Medical Center
-
-
South Carolina
-
Myrtle Beach, South Carolina, Forente stater, 29572
- Rekruttering
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Sarah Cannon Research Institute
-
Nashville, Tennessee, Forente stater, 37209
- Rekruttering
- Urology Associates
-
-
Texas
-
Austin, Texas, Forente stater, 78758
- Rekruttering
- NEXT Oncology
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- MD Anderson Cancer Center
-
-
Virginia
-
Norfolk, Virginia, Forente stater, 23502
- Rekruttering
- Virginia Clinical Research
-
-
-
-
-
Sutton, Storbritannia, SM2 5PT
- Rekruttering
- The Royal Marsden NHS Trust
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Patients must meet the following criteria to be eligible study participation:
Key Inclusion Criteria:
All Study Arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):
Males ≥ 18 years old Histological, pathological, and/or cytological confirmation of prostate adenocarcinoma Adequate hematological, renal, and hepatic function. Able to swallow oral medication
mCRPC Arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Prior orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testosterone Progressive mCRPC defined as having demonstrated PSA progression on the prior regimen
SOAR Arm (Phase 2 Part 2A) mHSPC with distant metastatic disease based on conventional imaging PSA ≥0.2 ng/mL, following treatment with next generation ARPI for at least 180 days and up to 365 days No evidence of radiographic or PSA progression while receiving ARPI
mHSPC arms (Phase 2 Part 2B, 2C & 2D) serum testosterone >150ng/ml mHSPC with distant metastatic disease based on conventional imaging and PSA >2.0 ng/mL
Key Exclusion Criteria:
All arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):
Has experienced a recent major bleed or has a known bleeding disorder Tumors exhibiting neuroendocrine or small cell carcinoma component by histopathology Receiving continuous corticosteroids at prednisone-equivalent dose of >10 mg/day Prior or ongoing significant medical condition
mCRPC arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Has received systemic anti-cancer therapy or investigational drugs within 2 weeks prior to first dose of study drug with certain exceptions requiring longer washout periods
SOAR arm (Phase 2 Part 2A) Has received any prior cytotoxic chemotherapy for prostate cancer
mHSPC arms (Phase 2 Part 2B, 2C & 2D) regional pelvic lymph node disease only
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: JNJ-101556143 Phase 1 Part 1 - Dose Escalation
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
Eksperimentell: JNJ-101556143 Phase 1 Part 2 - Formulation Exploration
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 Experimental: Oral JNJ-101556143 Experimental: Oral JNJ-101556143 |
|
Eksperimentell: JNJ-101556143 Phase 2 Part 1 - Dose Optimization
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
Eksperimentell: Phase 2 Part 2A - SOAR
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
Eksperimentell: Phase 2 Part 2B - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
Eksperimentell: Phase 2 Part 2C - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
Eksperimentell: Phase 2 Part 2D - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Frequency of dose-limiting toxicities (DLTs)
Tidsramme: 21 days
|
21 days
|
|
Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baseline
Tidsramme: 21 days
|
21 days
|
|
Phase 1 Part 2 (formulation exploration) relative bioavailability
Tidsramme: 22 days
|
22 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
PK Parameters
Tidsramme: 21 days
|
21 days
|
|
|
Duration of Response (DOR)
Tidsramme: 21 days
|
21 days
|
|
|
Radiographic Progression-Free Survival (rPFS)
Tidsramme: 63 days
|
63 days
|
|
|
Time to Response (TTR)
Tidsramme: 63 days
|
63 days
|
|
|
Change in PSA over time
Tidsramme: 21 days
|
Including PSA50 and PSA90 response |
21 days
|
|
Objective Response Rate (ORR)
Tidsramme: 63 days
|
Per RECIST in evaluable patients |
63 days
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Neoplasmer etter nettsted
- Neoplasmer
- Prostata sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Neoplasmer etter histologisk type
- Prostatiske neoplasmer
- Neoplasmer, kjertel og epitel
- Urogenitale neoplasmer
- Genitale neoplasmer, hanner
- Mannlige urogenitale sykdommer
- Kjønnssykdommer, mannlige
Andre studie-ID-numre
- HLD-0915-ONC-101
- HLD-0915-ONC-101 (Annen identifikator: Janssen Research & Development, LLC)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .